Evidence of jak2 val617phe positive essential thrombocythemia with splanchnic thrombosis during estroprogestinic treatment

Blood Coagulation and Fibrinolysis

Volumn 19, Issue 5, 2008, Pages 453-457

  Lapecorella, Mario ^a   Tabilio, Antonio ^a   Lucchesi, Alessandro ^a   Napolitano, Mariasanta ^a   Colagrande, Marianna ^a   Di Ianni, Mauro ^a   Mariani, Guglielmo ^a  

^a SAN SALVATORE HOSPITAL   (Italy)

Author keywords

Essential thrombocythemia; Janus kinase 2; Oral contraceptives; Portal thrombosis

Indexed keywords

ANTITHROMBIN; DOMPERIDONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; FIBRINOGEN; HEPARIN; HYDROXYUREA; JANUS KINASE 2; PHENYLALANINE; VALINE; WARFARIN;

ABDOMINAL PAIN; ADULT; ARTICLE; BLOOD CELL COUNT; BLOOD CLOTTING TIME; BONE MARROW BIOPSY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DEEP VEIN THROMBOSIS; ECHOGRAPHY; FEMALE; FIBRINOGEN BLOOD LEVEL; GENE MUTATION; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; INTERNATIONAL NORMALIZED RATIO; MEGAKARYOCYTE; MESENTERIC VEIN THROMBOSIS; ORAL CONTRACEPTION; PARTIAL THROMBOPLASTIN TIME; PORTAL VEIN BLOOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; SPLANCHNIC BLOOD FLOW; SUPERIOR MESENTERIC VEIN; THROMBOCYTE COUNT; THROMBOCYTHEMIA;

ADULT; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; HUMANS; JANUS KINASE 2; MESENTERIC VEINS; MUTATION, MISSENSE; SPLANCHNIC CIRCULATION; THROMBOCYTOPENIA; THROMBOSIS;

EID: 67649563149     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3283079e46     Document Type: Article

References (32)

1. Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med 1976; 295:913-916.
2. Gilliland DG, Blanchard KL, Levy J, Perrin S, Bunn HF. Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction. Proc Natl Acad Sci U S A 1991; 88:6848-6852.
3. Panani AD. Cytogenetic findings in untreated patients with essential thrombocythemia. In Vivo 2006; 20:381-384.
4. Steensma DP, Tefferi A. Cytogenetic and molecular genetic aspects of essential thrombocythemia. Acta Haematol 2002; 108:55-65.
5. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365:1054-1061.
6. Bellosillo B, Martinez-Aviles L, Gimeno E, Florensa L, Longaron R, Navarro G, et al. A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis. Leukemia 2007; 21:1331-1332.
7. Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V, et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 2006; 108:1865-1867.
8. Levine RL, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P, et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 2006; 107:4139- 4141.
9. Villmow T, Kemkes-Matthes B, Matzdorff AC. Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes. Thromb Res 2002; 108:139-145.
10. Falanga A, Marchetti M, Evangelista V, Vignoli A, Licini M, Balicco M, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000; 96:4261- 4266.
11. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366:1945-1953.
12. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 2006; 91:169-175.
13. Robertson B, Urquhart C, Ford I, Townend J,Watson HG, Vickers MA, et al. Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V6I7 F status, clonality, and antiphospholipid antibodies. J Thromb Haemost 2007; 5:1679-1685.
14. Di Ianni M, Moretti L, Del Papa B, Gaozza E, Bell AS, Falzetti F, et al. A microelectronic DNA chip detects the V617F JAK-2 mutation in myeloproliferative disorders. Leukemia 2006; 20:1895-1897.
15. Colaizzo D, Amitrano L, Tiscia GL, Scenna G, Grandone E, Guardascione MA, et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 2007; 5:55-61.
16. De Stefano V, Fiorini A, Rossi E, Za T, Farina G, Chiusolo P, et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007; 5:708-714.
17. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353:33-45.
18. Helmerhorst FM, Bloemenkamp KW, Rosendaal FR, Vandenbroucke JP. Oral contraceptives and thrombotic disease: risk of venous thromboembolism. Thromb Haemost 1997; 78:327-333.
19. Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldorp S, Helmerhorst FM, Bouma BN, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344:1527-1535.
20. Bar J, Lahav J, Hod M, Ben-Rafael Z, Weinberger I, Brosens J. Regulation of platelet aggregation and adenosine triphosphate release in vitro by 17beta-estradiol and medroxyprogesterone acetate in postmenopausal women. Thromb Haemost 2000; 84:695-700.
21. Feuring M, Christ M, Roell A, Schueller P, Losel R, Dempfle CE, et al. Alterations in platelet function during the ovarian cycle. Blood Coagul Fibrinolysis 2002; 13:443-447.
22. Roell A, Schueller P, Schultz A, Losel R, Wehling M, Christ M, et al. Effect of oral contraceptives and ovarian cycle on platelet function. Platelets 2007; 18:165-170.
23. Lapecorella M, Orecchioni A, Dell'Orso L, Mariani G. Upper extremity deep vein thrombosis after suspension of progesterone-only oral treatment. Blood Coagul Fibrinolysis 2007; 18:513-517.
24. Khetawat G, Faraday N, Nealen ML, Vijayan KV, Bolton E, Noga SJ, et al. Human megakaryocytes and platelets contain the estrogen receptor beta and androgen receptor (AR): testosterone regulates AR expression. Blood 2000; 95:2289-2296.
25. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996; 312:83-88.
26. Grandone E, Colaizzo D, Tiscia GL, Vergura P, Chinni E, Iannaccone L, et al. Venous thrombosis in oral contraceptive users and the presence of the JAK2 V617F mutation. Thromb Haemost 2008; 99:640-642.
27. Amitrano L, Guardascione MA, Ames PR, Margaglione M, Antinolfi I, Iannaccone L, et al. Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: relationship with splanchnic vein thrombosis and arterial disease. Am J Hematol 2003; 72:75-81.
28. Gale RE, Allen AJ, Nash MJ, Linch DC. Long-term serial analysis of X-chromosome inactivation patterns and JAK2 V617F mutant levels in patients with essential thrombocythemia show that minor mutant-positive clones can remain stable for many years. Blood 2007; 109:1241-1243.
29. Proietti C, Salatino M, Rosemblit C, Carnevale R, Pecci A, Kornblihtt AR, et al. Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells. Mol Cell Biol 2005; 25:4826-4840.
30. Teofili L, Martini M, Cenci T, Petrucci G, Torti L, Storti S, et al. Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation. Blood 2007; 110:354-359.
31. Roder S, Steimle C, Meinhardt G, Pahl HL. STAT3 is constitutively active in some patients with polycythemia rubra vera. Exp Hematol 2001; 29:694- 702.
32. Abel GA, Deangelo DJ, Connors JM, Sholl LM, McCaffrey RP, Longtine JA. Clinical JAK2V617F mutation testing: Limited utility for general hospital patients with venous and arterial thromboses in common locations. Am J Hematol 2008; 83:519-520.